Stockscreener 앱 받기
38.88
0.44%
-0.17
시장 영업 전:
38.87
-0.01
-0.03%
전일 마감가:
$39.05
열려 있는:
$39.05
하루 거래량:
922.23K
시가총액:
$6.63B
수익:
$29.52M
순이익/손실:
$-436.37M
주가수익비율:
-11.93
EPS:
-3.26
순현금흐름:
$-358.30M
1주 성능:
+4.29%
1개월 성능:
+24.34%
6개월 성능:
+80.92%
1년 성능:
+59.74%
1일 변동 폭
$38.38
$39.31
52주 변동 폭
$15.44
$40.21
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
650-481-6801
주소
700 Saginaw Drive, Redwood City, CA
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
GlobeNewswire Inc.
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Top 3 Health Care Stocks That May Collapse In Q2
Benzinga
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
GlobeNewswire Inc.
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
GlobeNewswire Inc.
Revolution Medicines Inc (RVMD) 재무 분석
Revolution Medicines Inc (RVMD) 매출 2024
RVMD은 2023-06-30 종료 분기에 대해 매출(지난 12개월)이 29.52M 달러로 보고했으며, 전년대비 +8.33% 상승했습니다.
Revolution Medicines Inc (RVMD) 순이익 2024
RVMD은 2023-12-31 종료 분기에 대해 순이익(지난 12개월)이 -436.37M 달러로 보고했으며, 전년대비 -75.46% 감소했습니다.
Revolution Medicines Inc (RVMD) 현금흐름 2024
2023-12-31 종료 분기에 RVMD은 현금흐름(지난 12개월)으로 -358.30M 달러를 기록했으며, 전년 대비 -52.33% 감소했습니다.
Revolution Medicines Inc (RVMD) 주당 순이익 2024
RVMD이 보고한 2023-12-31 종료 분기의 주당 순이익(지난 12개월)은 -3.84달러이며, 전년 대비 -23.87% 감소했습니다.
Revolution Medicines Inc 주식 (RVMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Anders Jack | Chief Financial Officer |
May 03 '24 |
Option Exercise |
2.68 |
10,000 |
26,800 |
111,959 |
| Anders Jack | Chief Financial Officer |
May 03 '24 |
Sale |
40.03 |
10,000 |
400,260 |
101,959 |
| Patel Sushil | Director |
Apr 10 '24 |
Option Exercise |
16.80 |
2,155 |
36,204 |
17,855 |
| GOLDSMITH MARK A | See Remarks |
Apr 10 '24 |
Sale |
35.33 |
10,000 |
353,346 |
30,424 |
| GOLDSMITH MARK A | See Remarks |
Apr 10 '24 |
Sale |
35.48 |
7,500 |
266,122 |
452,879 |
| Patel Sushil | Director |
Apr 10 '24 |
Sale |
37.00 |
2,155 |
79,735 |
15,700 |
| Cislini Jeff | General Counsel |
Mar 27 '24 |
Sale |
30.99 |
1,500 |
46,481 |
54,374 |
| GOLDSMITH MARK A | See Remarks |
Mar 18 '24 |
Sale |
31.58 |
5,788 |
182,804 |
460,379 |
| Horn Margaret A | Chief Operating Officer |
Mar 18 '24 |
Sale |
31.58 |
2,914 |
92,033 |
139,553 |
| Kelsey Stephen Michael | See Remarks |
Mar 18 '24 |
Sale |
31.58 |
2,123 |
67,051 |
270,909 |
0.58%
1.18%
자본화:
|
볼륨(24시간):